Replies to post #34548 on RespireRx Pharmaceuticals Inc (RSPI)

[davidal66]

This is actually an interesting thesis. A semi-buyout. How could it work? Garner some good data in apnea, then sell out all of the low impacts for say 40-50 million... well above the market cap, but that could change with apnea.

So you out-license everything in the low impact universe, and with the cash focus strictly on high impacts with the additional help of orphan drug groups like the Huntington's group, fragile X ect.... In fact you could go the following route. With the 'low impact money' work with fragile x/Huntington's groups and, perhaps on a larger scale, with the Michael J Fox group. The goal would be to get a high impact through toxicity and also into phase I in something like Huntington's/Fragile X. By definition, a positive neurodegeneration effect here would or could work on the larger Alzheimer's group.

I think Cortex might be able to control small niche conditions better than apnea and ADHD or Alzheimer's.

So the stock price would rebound perhaps enough for those who want to get off the train at 50 cents with the semi-buyout scenario. Cortex would then focus on orphan drug indications in house with the high impacts. Throw in a reverse split after some good news events and it kind of does make sense. Anything but continuation of the status quo ante.